Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Stubbs

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
British Journal of Haematology|March 29, 2019
Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpuraMatthew J Stubbs, Ryan Low, Siobhan McGuckin, et al.
British Journal of Haematology|April 17, 2022
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpuraAndrew J Doyle, Matthew J Stubbs, Will Lester, et al.
Blood|November 2, 2022
Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapyAndrew J Doyle, Matthew J Stubbs, Tina Dutt, et al.
Haematologica|February 18, 2021
Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpuraMatthew J Stubbs, Paul Coppo, Chris Cheshire, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
British Journal of Haematology|March 29, 2019
Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpuraMatthew J Stubbs, Ryan Low, Siobhan McGuckin, et al.
British Journal of Haematology|April 17, 2022
The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpuraAndrew J Doyle, Matthew J Stubbs, Will Lester, et al.
Blood|November 2, 2022
Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapyAndrew J Doyle, Matthew J Stubbs, Tina Dutt, et al.
Haematologica|February 18, 2021
Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpuraMatthew J Stubbs, Paul Coppo, Chris Cheshire, et al.
Pageof 1